Novo Nordisk reports positive cardiovascular outcomes data for Tresiba

Novo Nordisk has announced the results of a new clinical trial demonstrating the strong cardiovascular safety performance of its diabetes therapy Tresiba.

Headline results from the DEVOTE trial, which involved more than 7,500 people with type 2 diabetes, showed that Tresiba was non-inferior in terms of heart health to insulin glargine U100 when added to standard of care.

In the trial, type 2 diabetes patients at a high risk of major adverse cardiovascular events – including cardiovascular death, myocardial infarction or stroke – were treated for a period of approximately two years.

Tresiba patients experienced 27 percent fewer episodes of severe hypoglycaemia, resulting in a 40 percent overall reduction of total episodes of adjudicated severe hypoglycaemia overall.

Mads Krogsgaard Thomsen, executive vice-president and chief science officer of Novo Nordisk, said: "The DEVOTE results further strengthen the potential of Tresiba to become the new standard of care within basal insulin therapy."

Detailed results from the DEVOTE trial will be presented at a forthcoming scientific, with the findings to be submitted for review with regulatory authorities during the first half of 2017.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.